Regerna Therapeutics
- Biotech or pharma, therapeutic R&D
Regenerative medicine muscle repair and regeneration company built on a deep understanding of mRNA-binding proteins. Clinical candidate, AUF1, known master regulator of muscle repair and regeneration. Potential to revolutionize the treatment of genetic, traumatic and age-related muscle disorders.
Supplementing AUF1 results in benefits across all components necessary for full restoration of active, functional muscle - including meaningful and measurable re-innervation, increase in blood vessels and muscle stem cells, and improvement of mitochondrial function.
Utilizing LNP delivery to address post-injury and surgical disuse atrophy. Longer-term this includes muscular atrophy (e.g., aging associated atrophy), degenerative and neuromuscular diseases, muscle loss from GLP-1 agonist therapies, and volumetric muscle loss. Utilizing AAV delivery to address sub-segments of muscular dystrophies that are not adequately addressed. Expect to be in clinical development within two years.
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
){kind=logo}